Financial Performance - Operating revenue increased by 15.81% to CNY 68,240,881.12 for the first quarter of 2024, up from CNY 58,924,811.64 in the same period last year[12] - Net profit attributable to shareholders rose by 53.91% to CNY 8,654,939.61, compared to CNY 5,623,307.50 in Q1 2023[12] - The net profit margin improved, with net profit increasing by 52.26% to CNY 8,561,888.47[14] - Total operating revenue for Q1 2024 reached ¥68,240,881.12, a 15.5% increase from ¥58,924,811.64 in Q1 2023[34] - Net profit for Q1 2024 was ¥8,561,888.47, representing a 52.5% increase compared to ¥5,623,307.50 in Q1 2023[36] - Operating profit for Q1 2024 was ¥10,319,424.76, up 75.8% from ¥5,870,082.74 in Q1 2023[36] - The total profit for Q1 2024 was ¥10,320,989.76, a 75.5% increase from ¥5,872,903.73 in Q1 2023[36] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 10,721,174.48, a decrease of 46.10% year-on-year[14] - Cash inflow from operating activities for Q1 2024 was CNY 71,388,750.19, an increase from CNY 59,459,974.19 in Q1 2023, representing a growth of approximately 19.4%[41] - The net cash flow from operating activities for Q1 2024 was -CNY 10,721,174.48, an improvement compared to -CNY 19,892,433.69 in Q1 2023, indicating a reduction in losses by about 46.1%[41] - Cash inflow from investment activities in Q1 2024 totaled CNY 115,627,354.17, significantly higher than CNY 48,921,252.22 in Q1 2023, marking an increase of approximately 136.3%[43] - The net cash flow from investment activities for Q1 2024 was -CNY 7,453,702.31, an improvement from -CNY 40,127,671.53 in Q1 2023, reflecting a reduction in losses by about 81.4%[43] - Cash outflow from financing activities in Q1 2024 was CNY 10,288,734.66, compared to CNY 6,081,067.92 in Q1 2023, representing an increase of approximately 69.3%[43] Assets and Liabilities - Total assets decreased by 3.39% to CNY 437,725,635.66 as of March 31, 2024, compared to CNY 453,093,129.65 at the end of 2023[12] - The company reported a total current asset of 252,728,292.63 yuan as of March 31, 2024, down from 294,402,629.11 yuan at the end of 2023[28] - Current liabilities decreased from ¥55,844,213.67 to ¥28,750,898.50, a reduction of about 48.7%[29] - Non-current liabilities increased from ¥3,874,085.13 to ¥5,462,061.79, an increase of approximately 41%[30] - Total liabilities decreased from ¥59,718,298.80 to ¥34,212,960.29, a decrease of about 42.7%[30] - Shareholders' equity increased from ¥393,374,830.85 to ¥403,512,675.37, an increase of approximately 2.9%[30] Shareholder Information - The total number of shares outstanding is 75,631,404, with 25.00% being unrestricted shares and 75.00% being restricted shares[19] - Major shareholders include Zhao Zhuojun with 41.22% and Wu Li with 27.43% of the total shares[19] - The company maintains a stable shareholder structure with no pledged or frozen shares reported[21] Other Financial Metrics - The weighted average return on equity increased to 2.18% from 1.43% in the previous year[12] - Research and development expenses decreased to ¥2,619,655.80 in Q1 2024, down 24.7% from ¥3,482,350.98 in Q1 2023[34] - Other income increased to ¥448,633.06 in Q1 2024, up 97.1% from ¥227,455.28 in Q1 2023[34] - The company reported a foreign exchange gain of ¥309,669.30 in Q1 2024, compared to a gain of ¥137,200.42 in Q1 2023[34] - The company recorded a tax expense of ¥1,759,101.29 for Q1 2024, significantly higher than ¥249,596.23 in Q1 2023[36] - Non-recurring gains and losses amounted to CNY 515,292.84 after tax, reflecting various adjustments and government subsidies[16] Inventory and Receivables - Accounts receivable increased from 63,263,660.23 yuan to 68,130,075.97 yuan, indicating a growth of approximately 10%[28] - Inventory slightly increased from 73,931,694.95 yuan to 74,387,598.57 yuan[28] - Inventory decreased slightly from ¥74,387,598.57 to ¥73,931,694.95, a decrease of about 0.6%[31] - The company reported a significant increase in prepayments for raw material purchases, rising by 193.05% to CNY 10,041,006.97[13] - The company experienced a 142.59% increase in contract liabilities, indicating a rise in advance payments for product sales[13]
欧康医药(833230) - 2024 Q1 - 季度财报